Inghirami G - Search Results

1

Anaplastic lymphoma kinase in human cancer.

Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, Kwee I, Bertoni F, Piccaluga PP, Pileri SA, Inghirami G; European T-Cell Lymphoma Study Group. Barreca A, et al. Among authors: inghirami g. J Mol Endocrinol. 2011 Jul 4;47(1):R11-23. doi: 10.1530/JME-11-0004. Print 2011 Aug. J Mol Endocrinol. 2011. PMID: 21502284 Review.

2

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.

Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G. Zamo A, et al. Among authors: inghirami g. Oncogene. 2002 Feb 7;21(7):1038-47. doi: 10.1038/sj.onc.1205152. Oncogene. 2002. PMID: 11850821

3

S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase.

Chiarle R, Fan Y, Piva R, Boggino H, Skolnik J, Novero D, Palestro G, De Wolf-Peeters C, Chilosi M, Pagano M, Inghirami G. Chiarle R, et al. Among authors: inghirami g. Am J Pathol. 2002 Apr;160(4):1457-66. doi: 10.1016/S0002-9440(10)62571-0. Am J Pathol. 2002. PMID: 11943729 Free PMC article.

4

In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation.

Piva R, Liu J, Chiarle R, Podda A, Pagano M, Inghirami G. Piva R, et al. Among authors: inghirami g. Mol Cell Biol. 2002 Dec;22(23):8375-87. doi: 10.1128/MCB.22.23.8375-8387.2002. Mol Cell Biol. 2002. PMID: 12417738 Free PMC article.

5

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, Simmons WJ, Dhall G, Howes J, Piva R, Inghirami G. Chiarle R, et al. Among authors: inghirami g. Blood. 2003 Mar 1;101(5):1919-27. doi: 10.1182/blood-2002-05-1343. Epub 2002 Nov 7. Blood. 2003. PMID: 12424201 Free article.

6

New and old functions of STAT3: a pivotal target for individualized treatment of cancer.

Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. Inghirami G, et al. Cell Cycle. 2005 Sep;4(9):1131-3. doi: 10.4161/cc.4.9.1985. Epub 2005 Sep 30. Cell Cycle. 2005. PMID: 16082218 Review.

7

p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.

Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hirsch E, Boeri Erba E, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. Ambrogio C, et al. Among authors: inghirami g. Blood. 2005 Dec 1;106(12):3907-16. doi: 10.1182/blood-2005-03-1204. Epub 2005 Aug 16. Blood. 2005. PMID: 16105984 Free PMC article.

8

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.

Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G. Piva R, et al. Among authors: inghirami g. Blood. 2006 Jan 15;107(2):689-97. doi: 10.1182/blood-2005-05-2125. Epub 2005 Sep 27. Blood. 2006. PMID: 16189272 Free PMC article.

9

Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, Costa G, Ruggeri BA, Cheng M, Chiarle R, Palestro G, Neri A, Inghirami G. Piva R, et al. Among authors: inghirami g. J Clin Invest. 2006 Dec;116(12):3171-82. doi: 10.1172/JCI29401. Epub 2006 Nov 16. J Clin Invest. 2006. PMID: 17111047 Free PMC article.

10

Identification and validation of the anaplastic large cell lymphoma signature.

Piva R, Pellegrino E, Inghirami G. Piva R, et al. Among authors: inghirami g. Adv Exp Med Biol. 2007;604:129-36. doi: 10.1007/978-0-387-69116-9_12. Adv Exp Med Biol. 2007. PMID: 17695725

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

321 results

Search Page